MLH1 and cancer: Amsterdam-II or Bethesda criteria used to identify MLH1/MHS2/MSH6 carriers in clinical practice miss 55–70% or 12–30% (respectively) of these MLH1/MHS2/MSH6 carriers [65] even amongst those with cancer.